A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism
Authors:
- Karen J. ParkerKPKaren J. Parker
- Ozge OztanOOOzge Oztan
- Debra S. KarhsonDKDebra S. Karhson
- Raena D. SumiyoshiRSRaena D. Sumiyoshi
- Jacqueline E. SummersJSJacqueline E. Summers
- Kyle E. HinmanKyle E. Hinman
- Kara S. MotonagaKMKara S. Motonaga
- Jennifer M. PhillipsJPJennifer M. Phillips
- Lawrence K. FungLFLawrence K. Fung
Top Cited Papers
Open Access
- 8 May 2019
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 11 (491)
Abstract
The social impairments of autism spectrum disorder (ASD) have a major impact on quality of life, yet there are no medications that effectively treat these core social behavior deficits. Preclinical research suggests that arginine vasopressin (AVP), a neuropeptide involved in promoting mammalian social behaviors, may be a possible treatment for ASD. Using a double-blind, randomized, placebo-controlled, parallel study design, we tested the efficacy and tolerability of a 4-week intranasal AVP daily treatment in 30 children with ASD. AVP-treated participants aged 6 to 9.5 years received the maximum daily target dose of 24 International Units (IU); participants aged 9.6 to 12.9 years received the maximum daily target dose of 32 IU. Intranasal AVP treatment compared to placebo enhanced social abilities as assessed by change from baseline in this phase 2 trial’s primary outcome measure, the Social Responsiveness Scale, 2nd Edition total score (SRS-2 T score; F1,20 = 9.853; P = 0.0052; ηp2 = 33.0%; Cohen’s d = 1.40). AVP treatment also diminished anxiety symptoms and some repetitive behaviors. Most of these findings were more pronounced when we accounted for pretreatment AVP concentrations in blood. AVP was well tolerated with minimal side effects. No AVP-treated participants dropped out of the trial, and there were no differences in the rate of adverse events reported between treatment conditions. Last, no changes from baseline were observed in vital signs, electrocardiogram tracings, height and body weight, or clinical chemistry measurements after 4 weeks of AVP treatment. These preliminary findings suggest that AVP has potential for treating social impairments in children with ASD.Keywords
Funding Information
- National Institute of Mental Health (R21MH100387)
- National Institute of Mental Health (T32MH019908)
- National Institute of Mental Health (K08MH111750)
- Autism Speaks (7895)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R21HD083629)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD091972)
- Stanford’s Department of Psychiatry (N/A)
- The Teresa and Charles Michael Endowed Fund for Autism Research and Education (N/A)
- Child Health Research Institute, University of Nebraska Medical Center (N/A)
- Stanford’s Department of Psychiatry (N/A)
- Child Health Research Institute, University of Nebraska Medical Center (N/A)
- The Yani Calmidis Memorial Fund for Autism Research (N/A)
- Mosbacher Family Fund for Autism Research (N/A)
- Stanford’s Department of Psychiatry (N/A)
- Bass Society (N/A)
This publication has 65 references indexed in Scilit:
- Transcutaneous electrical acupoint stimulation in children with autism and its impact on plasma levels of arginine-vasopressin and oxytocin: A prospective single-blinded controlled studyResearch in Developmental Disabilities, 2012
- ENU mutagenesis reveals that Notchless homolog 1 (Drosophila) affects Cdkn1a and several members of the Wnt pathway during murine pre-implantation developmentBMC Genetics, 2012
- The Quantitative Nature of Autistic Social ImpairmentPediatric Research, 2011
- Central vasopressin V1a receptor activation is independently necessary for both partner preference formation and expression in socially monogamous male prairie voles.Behavioral Neuroscience, 2010
- Anterior hypothalamic vasopressin regulates pair-bonding and drug-induced aggression in a monogamous rodentProceedings of the National Academy of Sciences, 2009
- Genomic and epigenetic evidence for oxytocin receptor deficiency in autismBMC Medicine, 2009
- The NimStim set of facial expressions: Judgments from untrained research participantsPsychiatry Research, 2009
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Anxiety in children and adolescents with autism spectrum disordersClinical Psychology Review, 2009
- Profound Impairment in Social Recognition and Reduction in Anxiety-Like Behavior in Vasopressin V1a Receptor Knockout MiceNeuropsychopharmacology, 2003